Lilly Asia Ventures returned for a series C round that pushed the cancer immunotherapy developer's overall funding to the $260m mark.

China-based immuno-oncology therapy developer Elpiscience Biopharma closed a $105m series C round yesterday that included Lilly Asia Ventures, a corporate venture capital vehicle for pharmaceutical firm Eli Lilly.

Greater Bay Area Homeland Development Fund led the round, which also featured Cormorant Asset Management, Maison Capital, Superstring Capital, Pluto Connection, Unifortune Fund and existing backers including CDH Investments, Dyee Capital and Oriza Holdings.

Elpiscience is developing immunotherapies to treat cancer and has three antibody drug candidates – ES101, ES102 and ES104…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn